Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5965-5971

  Le Tourneau, Christophe ^a   Michiels, Stefan ^a   Gan, Hui K ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EVENT FREE SURVIVAL; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; NECK DISSECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; STANDARDIZATION; TIME SERIES ANALYSIS; TREATMENT FAILURE; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BIOASSAY; DISEASE COURSE; HEAD AND NECK TUMOR; MORTALITY; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; SURVIVAL; TIME; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HEAD AND NECK NEOPLASMS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 73349143339     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.3685     Document Type: Article

References (21)

1. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-639, 1996
2. Moher D, Schulz KF, Altman D: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285:1987-1991, 2001
3. Pazdur R: Endpoints for assessing drug activity in clinical trials. Oncologist 13:S19-S21, 2008 (suppl 2)
4. Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, et al: Survival end point reporting in randomized cancer clinical trials: A review of major journals. J Clin Oncol 26:3721-3726, 2008
5. Schellhammer P, Cockett A, Boccon-Gibod L, et al: Assessment of endpoints for clinical trials for localized prostate cancer. Urology 49:27-38, 1997
6. Punt CJ, Buyse M, Köhne CH, et al: Endpoints in adjuvant treatment trials: A systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998-1003, 2007
7. Allegra C, Blanke C, Buyse M, et al: End points in advanced colon clinical trials: A review and proposal. J Clin Oncol 25:3572-3575, 2007
8. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007
9. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711, 2008
10. Chua YJ, Sargent D, Cunningham D: Definition of disease-free survival: This is my truth-show me yours. Ann Oncol 16:1719-1721, 2005
11. Cuzick J: Primary endpoints for randomised trials of cancer therapy. Lancet 371:2156-2158, 2008
12. Bentzen SM: Towards evidence based radiation oncology: Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 46:5-18, 1998
13. Haddad RI, Shin DM: Recent advances in head and neck cancer. N Engl J Med 359:1143-1154, 2008
14. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three metaanalyses of updated individual data - MACH-NC Collaborative Group; Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
15. Pignon JP, le Maître A, Bourhis J: Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 69:S112-S114, 2007 (suppl 2)
16. Bourhis J, Overgaard J, Audry H, et al: Hyper-fractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843-854, 2006
17. Michiels S, Le Maître A, Buyse M, et al: Surrogate endpoints for overall survival in locally advanced head and neck cancer: Meta-analyses of individual patient data. Lancet Oncol 10:341-350, 2009
18. Wadsley JC, Bentzen SM: Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 60:1405-1409, 2004
19. Vedrine PO, Thariat J, Hitier M, et al: Need for neck dissection after radiochemotherapy? A study of the French GETTEC Group. Laryngoscope 118: 1775-1780, 2008
20. Panageas KS, Ben-Porat L, Dickler MN, et al: When you look matters: The effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99:428-432, 2007
21. Radiation Therapy Oncology Group: RTOG 0522: A randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab (c225) [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. http://www.rtog.org/ members/protocols/0522/0522.pdf